Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTIVATE: DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
NCT06858579Phase 3Recruiting
- Sponsor
- Dianthus Therapeutics
- Start
- Feb 2025
- Primary completion
- Dec 2028
- Countries
- 31
01
Overview
Phase 3, randomised, double-blind trial of claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) (4 arms), sponsored by Dianthus Therapeutics. Primary endpoint: Time From First Dose to Relapse as Assessed by the Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT). Started Feb 2025; status: recruiting.
02
Drugs
claseprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT06858579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06858579.